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ABSTRACT
Technological advancement in high-throughput genomics such as deoxyribonucleic
acid (DNA) and ribonucleic acid (RNA) sequencing has significantly increased the
size and the complexity of data-sets. Also, a high number of features (genes) with
a limited number of samples (patients) introduces a significant amount of noise in
the data. Modern deep learning algorithms in conjunction with high computational
power can handle those problems and are able to detect and diagnose diseases in a
short time with reduced chance of error. Thus, developing such method and pipeline
is of current research interest.
At the beginning of the research, high dimensionality problem of the dataset was
addressed and tried to overcome that problem by reducing the number of features
using various feature extraction methods. Thus adversarial autoencoder (AAE) based
feature extraction model has been introduced. Then the performance of the proposed
model is evaluated using classification and weight matrix. First, the AAE model
was tested using twelve various classifiers, and the results show significant perfor-
mance improvement in terms of precision and recall. Compared to all other methods,
AAE with support vector machine (SVM), decision tree (DT), k-nearest neighbours
(KNN), quadratic discriminat analysis (QDA) and xgboost (XGB) classifiers show
significant performance improvement in precision having score of 85.96%, 84.41%,
85.74%, 84.27% and 85.47% respectively. Most importantly, AAE provides consistent
results in all performance metrics across twelve different classifiers which makes this
feature extraction model classifier independent. Then, by analysing the weight ma-
trix of AAE, important biomarkers such as OR2T27, OR2A25, OR8B8 and OR6V1
are identified that belong to molecular function of olfactory receptor activity. Recent
study shows that olfactory receptor genes are highly expressed in breast carcinoma
tissues which validated our result.
xvii
Later, a pipeline has been developed for mutation identification using methylated
DNA dataset. For this, raw data is analysed and three different variant caller methods
are used to validate the results. Then common variants are taken for annotation to
extract biological information. Next, low-quality genes are filtered out and identified
22 mutated genes that are responsible for acute myeloid leukemia (AML) diseases.
Among them, most of the mutated genes are missense, non-synonymous and some
of them are stop-gain and non-frameshift. The mutation frequency of the mutated
genes are validated using DriverDB and Intogen databases. Here, three genes such
as ZFHX3, DOK2, and PKHD1 have mutation frequency of 0.51% found in AML
where rest of the mutated genes are novel for leukemia disease.
To summarise, it is shown in the experiment that the feature extraction method is
not only useful for diagnosing diseases, but it can be helpful for identifying biological
marker which can further assist in developing personalised medicine and selecting
a therapeutic target. Besides, variant analysis pipeline provides novel variant genes
which could enhance the understanding of the leukemia diseases and provide direction
for further clinical research and drug development.
1Chapter 1
Introduction
1.1 Background
The advent of next-generation sequencing (NGS) technologies has revolutionised
the genome sequencing applications for its higher efficiency and relatively low cost
as illustrated in Fig. 1.1. Using the whole genome sequencing (WGS) data, it is
possible to identify regulatory elements such as transcription factors and histones,
predict protein structure and single nucleotide polymorphism (SNPs). Since NGS
produces millions of sequencing reads, it raises complexity for storing and analysing
the data. Robust deep learning and statistical methods in combination with various
bioinformatics tools can be used to diagnose rare diseases and provide personalised
treatment.
Fig. 1.1. The cost of genome sequencing is decreasing since the last decade
[1].
21.2 Problem Statement
Deep learning has a number of significant applications in the field of bioinfor-
matics. Biological data is highly heterogeneous, often has many missing values and
require sophisticated tools to analyse. These complex nature of data can be han-
dled using deep learning-based algorithms [2]. Some of the problems regarding deep
learning while applying in the application of biological data are described below:
• Unsupervised deep learning shows excellent success in dimension reduction and
clustering techniques. However, this model needs to be optimised to incorporate
genetic data as the dataset is growing very fast (see Fig. 1.2). Also, it is difficult
to extract meaningful biological information as data contain thousands of genes.
Fig. 1.2. Nucleotide sequence, mass spectrometry, and microarray data
keep increasing [3].
• Biological omics data are heterogeneous as they contain many types of informa-
tion, such as genetic sequences, protein-protein interaction or electronic health
records. Besides, this data often has a relatively small sample size which pro-
vides biased results while applied deep learning methodologies.
31.3 Scope and Rationale of the research
As bioinformatics is a highly inter-discipline field, the research on next-generation
sequencing technique, feature extraction method and classification approach using
high-performance computing are becoming an essential part of genomic data analysis.
The primary purpose of this data-driven approach is to obtain biological meaning
from genetic data using various mathematical and statistical techniques. Due to the
complex nature of genetic data, deep learning methods are particularly well suited for
this kind of problem. Furthermore, deep learning has revolutionised several areas of
biology and medicine by examining the variety of issues such as diagnosing diseases,
protein integrations and drug discovery, which may aid the human investigation.
The complexity of biological data presents new challenges, but modern artificial
intelligence methods such as deep learning have increased the expertise of pathologist
by improving diagnostic accuracy. This study provides evidence that deep learning
based diagnosis can facilitate clinical decision making to detect cancer. Potential
benefits of using computer-aided diagnosis (CAD) include reduced diagnostic turn-
around time with increased accuracy. While achieving state of the art results and
even surpass human accuracy in many challenging tasks, but the adoption of deep
learning in bioinformatics using genomic data has been comparatively low. Due to
high dimensional data, the use of the deep neural network is suitable in this case,
and it outperforms classical machine learning techniques for cancer detection and
relevant gene identification. After successfully implementing this project, it will be
easier to assess the potential effectiveness of CAD to support clinical decision making.
Besides improving accuracy, the system will be able to detect potential markers for
cancer, identify genetically mutated genes, and recommend personalised medicine.
Finally, cancer patients, cancer researchers, and clinicians including pathologists and
oncologists will get benefit from this research.
41.4 Objectives of the Research
The research project deals with two different types of data for two separate anal-
ysis. The first analysis deals with normalised RNA-seq breast cancer data where
machine learning techniques are used to classify and identify the biomarker of cancer.
Second analysis deals with raw DNA methylated leukemia samples to determine the
mutations. The main objectives are:
• To develop a deep learning algorithm which can classify breast cancer subtypes
while extracting essential features about the disease.
• To obtain optimal hyper-parameters of the developed algorithm
• To create a pipeline for identifying novel mutations in leukemia samples
• To generate results and analyze the performance of proposed methods
1.5 Research Questions
Some of the questions which are answered in this work are:
1.5.1 Research Question 1
How to classify breast cancer sub-types while maintaining accuracy?
Significance
As cancer develops progressively, classification of cancer types at an early stage is
likely to be more effective and has the lowest chance of recurrence. Machine intelligent
based classification techniques can handle a large amount of data and much more
accurate than human-crafted rules. This classification algorithms can automatically
find the correlation in data and can assist pathologist to understand the extent of
diseases.
5Key Findings
Handling genetic data is crucial as this data has lots of features with a limited
amount of samples. Applying proper pre-processing techniques can make a signifi-
cant improvement in classification. Hence, AAE based feature extraction method is
developed which helps to improve performance in most of the classifiers.
1.5.2 Research Question 2
How to extract meaningful features to identify breast cancer biomarkers using
normalized RNA-seq datasets?
Significance
Identifying biomarkers are essential to understanding the spectrum of any dis-
eases. By extracting meaningful features and analysing the corresponding weight
matrix, relevant biomarkers can be identified which will help researchers in develop-
ing personalized medicine and selecting therapeutic targets.
relevant biomarkers can be identified, which will help.
Key Findings
AAE based feature extraction method not only assist in classifying cancer but it
encoded some essential genes. Those genes were analysed and ranked them according
to their weights. Finally, top 50 genes are taken for gene enrichment analysis. Recent
studies prove that molecular function of those genes show association with breast
cancer. It is found that AAE can reveal important biomarkers compared with current
state-of-the-art methods.
61.5.3 Research Question 3
What is the best a pipeline for detecting novel variants in raw DNA methylated
samples?
Significance
Genetic variations can act as biomarkers and able to locate genes associated with
diseases. The location of these biomarkers can be enormously important in terms of
predicting functional significance [4]. It also helps to identify individual response to
certain drugs thus able to determine targeted therapies.
Key Findings
Proposed pipelines have been applied to eight different leukemia samples and got
total of 22 novel variant genes. Their corresponding chromosome location is reported,
and functional analysis is performed. Finally, results reveal that those mutated genes
are known to be associated with AML.
1.6 Structure of the Thesis
The thesis is divided into five chapters namely Introduction, Literature review,
Feature extraction using adversarial autoencoder, Identification of novel mutations
using bioinformatics pipelines, and Conclusions.
Chapter 1 presents research background, problem statement, scope, rationale, objec-
tives, and research questions.
Chapter 2 provides a complete literature review and helps to identify the gaps in the
existing literature.
Chapter 3 outlines the methodology for breast cancer subtype classification and ex-
tracting biologically relevant genes from normalized RNA-seq data. The results and
experiments that have been conducted using the deep learning library such as Ten-
7sorflow, Keras, scikit-learn and programming languages such as python are also dis-
cussed.
Chapter 4 outlines the methodology of variant analysis of leukemia sample. All anal-
ysis was done using web-based tools called Galaxy. Deep learning-based model is also
applied for finding variants and results are compared with existing bioinformatics
tools.
Finally, in Chapter 5 overall conclusions on deep learning based feature extraction
method and variant analysis pipelines are summarized with recommendations for
future research studies.
8Chapter 2
Literature Review
2.1 Overview
This chapter reflects on the existing literature of various types of machine learning
models and their applications. It also exhibits various bioinformatics pipelines, tools,
and datatypes. First, review of deep learning methods such as supervised learning,
unsupervised learning, semi-supervised learning are presented. Then, different types
of deep learning models and their applications are discussed. Bioinformatics tools,
datatypes, and various pipelines are also reviewed in this chapter. Next, discussions
are drawn based on challenges and opportunities for machine learning in bioinformat-
ics. Finally, conclusions are drawn based on research gaps and critical findings.
2.2 Deep Learning Theoretical Background
2.2.1 Artificial Neural Network & Various types of Data Mining Methods
Deep learning is one of the significant areas in artificial intelligence that give
machines the ability to learn representations of data with multiple levels of abstraction
that discovers hidden structure in a large dataset [5]. The following Fig. 2.1 illustrates
the biological neuron that has dendrites which receive signals from other neurons,
summed them and forward these signals to axons. With the help of axons, these
signals are fired to the next neurons through which are known as synapse.
On the other hand in artificial neural network input nodes act as dendrites, ac-
tivation function act as axon and output layer act as a Synapse. Perceptron is an
artificial neuron which is similar to biological neurons, that has input nodes and a
single output node, which is connected to each input node. The machine can learn
9in supervised, unsupervised, and semi-supervised manner. Deep learning has many
applications in healthcare for example cancer detection, diagnosis in medical imag-
ing, drug discovery, robotic surgery, protein structure prediction, and personalised
medicine and treatment [6].
(Synapse)
Fig. 2.1. Biological neuron compared with the artificial neural network [7].
Supervised Learning
In supervised learning, the model takes a dataset that has the output variable,
and the learning algorithm is used to map the input dataset to the output so that
it can predict the fate of unknown instances [8]. Classification and regression are
the applications of supervised learning. For example, using supervised learning, clas-
sification algorithm will learn to identify diseases after being trained on a dataset
of genes that are correctly labelled. There are various supervised machine learning
algorithms, for example, random forest, linear and logistic regression, support vector
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machines that are commonly used for classification and regression steps. However, for
the excessively large dataset, deep neural network based classification and regression
algorithm are generally required to deal with data non-linearity.
Unupervised Learning
The goal of unsupervised learning is to map the underlying hidden structure of
the dataset where machine only receives inputs but do not receive any outputs [9].
This model is called unsupervised since dataset contains only input variables and does
not contain any label during the learning process. Unsupervised learning discovers
interesting structures in the data and common use of this is cluster and association
rule analysis [10] [11]. Some popular unsupervised algorithms are k-means, principal
component analysis (PCA), autoencoder for clustering problem and apriori algorithm
for the association rule learning problem. Here, autoencoder is a neural network
based unsupervised learning algorithm that has many applications such as clustering,
dimension reduction, and image denoising. Biological data often don’t have labels;
therefore, unsupervised learning is beneficial for clustering and helps to reduce the
dimension to facilitate further analysis [9].
Semi-Supervised Learning
Semi-supervised learning algorithms require both labelled and unlabeled data to
build complex machine learning models [12]. In real life, labelled data is quite ex-
pensive and labelling the data manually is time-consuming hence, including lots of
unlabeled data in combination with labelled data tends to improve the accuracy and
reduce biases from the model. Semi-supervised model shines in webpage classification,
speech recognition, or even for genetic engineering [13].
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2.2.2 Types of Neural Networks
Multi-Layer Perceptron
multilayer perceptron (MLP) is a supervised learning algorithm that can handle
nonlinearity and is required to solve complex tasks, unlike single perceptron [14].
With perception, it is possible to build a larger and more effective structure that can
be described as MLP and has at least three main layers; input layer, hidden layer,
and an output layer. It is also called a feedforward network since it has a direct
connection between all layers is shown in Figure 2.2.
Fig. 2.2. Multilayer perceptron with input layer, one hidden layer, and
output layer [15].
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Autoencoder
An autoencoder is a neural network based unsupervised learning algorithm (il-
lustrated in Fig. 2.3) that applies backpropagation, setting the target values to be
equal to the inputs and can extract non-linearities within the data. It can learn au-
tomatically from data examples, which means autoencoder does not require labelled
data. Some practical applications of autoencoders are data denoising and dimen-
sionality reduction from high dimensional data which is useful for data visualisation.
With appropriate dimensionality and sparsity constraints, autoencoders can learn
data projections that are more interesting than PCA or other basic techniques. Au-
toencoder has some drawbacks; for example, it can compress data similar to what
they have been trained on; therefore this method is data-specific. Also, autoencoders
are lossy, which means that the decompressed outputs will be degraded compared
to the original inputs. An encoding function, a decoding function, and a distance
function which is a loss between the compressed and the decompressed representa-
tion of data are required to build an autoencoder. The parameters of the encoding
and decoding functions can be optimised using stochastic gradient descent (SGD) to
minimise the reconstruction loss.
2.2.3 Training Neural Network using Backpropagation
Training a deep neural network is done using the back-propagation learning pro-
cedure [17]. Back-propagation algorithm repeatedly computes gradient in order to
minimize the cost function and update the weights of the network [18] [19]. Back-
propagation requires a forward pass and a backward pass for every considered training
example. After forward pass, the cost is calculated using cost function. During back-
propagation, partial derivatives (with respect to weight or bias) of that cost function
is computed to reduce the loss and adjust the weights and bias accordingly.
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Fig. 2.3. Autoencoder reconstruct actual input to its output layer and
encoded data stored in the hidden layer [16].
Various Gradient Descent Algorithms
Batch gradient descent: Batch gradient descent calculate gradient of the full
training set and update the model after all training sample have been evaluated [20].
This algorithm requires entire dataset loaded into memory which can be slow for big
datasets.
Stochastic gradient descent (SGD): SGD update parameters for each training
sample and it shows amazing performance in large scale problems [20] [21]. This
approach overcome problem where dataset is too big to fit in memory. Although SGD
performs frequent updates with high fluctuations, it can lead to a faster convergence.
Mini-batch gradient descent: Mini-batch gradient descent is a trade-off between
stochastic gradient descent and batch gradient descent. It splits the training dataset
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into small batch size range between 50 and 256 [22] that are used to calculate model
error and update model coefficients. Using small batches of data reduces fluctuations
of parameters during model updates compared to other two methods.
2.3 Bioinformatics Theoretical Background
2.3.1 Background
NGS has grown by leaps and bounds over the last decades. This technology had
high-throughput capabilities and revolutionised the landscape of genomic medicine
[23]. The rapidly decreasing cost of sequencing per genome has sparked growing
demand in the field of data analysis and machine learning in particular. The rapid
adoption of NGS technology is undoubtedly the gateway to the new era of personalised
treatment and cancer prognosis, hence NGS bioinformatics can provide a solution
for the next generation of molecular diagnostics. However, it is still a challenge
for researchers to analyse the NGS data and extract meaningful information from it
because of the high complexity and sparsity of the data. Deep learning is getting more
and more attention after being known to outperform commonly used bioinformatics
tools. Deep learning algorithm on NGS data revolutionise nowadays and lead to
potential discoveries that can help on clinical diagnosis and disease prognosis. In
this research, a deep learning based algorithm named deep-variant is used to find the
variant in DNA-methylated data in conjunction with traditional tools like freebayes,
genome analysis toolkit (GATK).
2.3.2 Molecular biology
DNA Nucleotides and Strands:
Deoxyribonucleic acid (DNA), is the genetic material in humans and almost all
other organisms that carried genetic code. All the biological information are stored
in the DNA. Most of the DNA is located in the cell nucleus, but a small amount
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of DNA can also be found in the mitochondria which are known as mitochondrial
DNA (mtDNA) [24]. DNA is a chainlike double helix, long molecule that has two
strands which are made up of simpler molecules called nucleotides. The nucleotide is
composed of four nitrogen-containing nucleobases such as cytosine (C), guanine (G),
adenine (A) and thymine (T). Nucleobases pair up with each other, A with T and C
with G to form units called base pairs. An important property of DNA is that it can
make copies of itself.
RNA (Ribonucleic Acid):
Ribonucleic acid (RNA) is a linear molecule responsible for the coding, decoding,
regulation, and expression of genes. Unlike DNA, RNA only has a single strand that
folds onto itself, and its sugar is called Ribose. It composed of four types of smaller
molecules called ribonucleotide bases: adenine (A), cytosine (C), guanine (G), and
uracil (U).
Gene Expression:
DNA contains genes, and those genes are used to produce RNA using the tran-
scription process. Information from a gene is used in the synthesis of a functional
gene product; this process is called gene expression [25]. A gene is a continuous
string of nucleotides that begins with a promoter and ends with a terminator shown
in Fig. 2.4. The process of transforming DNA into proteins is divided into two stages:
transcription and translation. In the transcription process, RNA is produced using
DNA templates, and during translation, proteins are synthesised using RNA tem-
plates shown in Fig. 2.5 [27].
A transcription process is carried out by RNA polymerase enzyme and many tran-
scription factors. The mRNA is formed during transcription contains coding and
non-coding sections which are known as exons and introns respectively. Since, the
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Fig. 2.4. Structure of a gene includes a promoter region, RNA-coding
region and terminator sites [26].
only exon contains information about protein, intros that are non-coding sections are
then removed by splicing [25].
Fig. 2.5. DNA transcribed into RNA, and this transcript may then be
translated into protein [28].
2.3.3 Various Pipelines in Bioinformatics
RNA-Seq Analysis
RNA sequencing (RNA-seq) is a high-throughput next generation sequencing tech-
nology that provides a comprehensive understanding of the transcriptome [29]. Pow-
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erful computational resources and good algorithms are required to perform this RNA-
Seq analysis [30]. The pipeline for differential gene analysis using RNA-Seq data is
shown below in Fig. 2.6. Several RNA-seq analysis pipelines have been proposed
to date. However, no single analysis pipeline can capture the dynamics of the en-
tire transcriptome. Here, a robust and commonly used analytical pipeline have been
compiled and presented which includes quality checks, alignment of reads, differential
gene expression analysis, the discovery of cryptic splicing events, and visualization.
First, after obtaining the raw reads in the sequencing process the reads are subjected
to a quality control step. In this step, FASTQC tools are used in order to check the
data and trim the data if necessary to improve further stages performance. After the
quality control step, the reads need to be aligned with a reference genome. Following
the alignment step, a quantification is performed. In this step, reads are aggregated
to calculate gene expression values to be then compared with other samples values in
the differential expression step in order to know what genes are most expressed.
Fig. 2.6. Pipeline for differential gene analysis using RNA-Seq data [31].
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DNA-Seq Analysis
NGS is becoming the most popular high throughput technology for biomedical
research, personalised treatment, and drug design for the diseases. It is empowering
genetic disease research and brings significant challenges for sequencing data analysis.
DNA-Seq pipeline using whole exome sequencing (WES) and WGS data, to detect
variants or mutations from disease samples shown in Fig. 2.7. DNA-seq data analysis
is to study genomic variants through aligning raw reads from NGS sequencing to a
reference genome and then apply variant call software to identify genomic mutations,
including SNPs, etc. [32]. The DNA-Seq analysis requires deep knowledge regarding
bioinformatics tools, High-performance computing (HPC) resources and the analysis
needs to be able to reproduce the results to facilitate comparisons as well as down-
stream analysis.
The pipeline starts with checking the quality of the sequence using FASTQC tools
Fig. 2.7. Pipeline for variant analysis using DNA-Seq data [33].
and apply trim adapters from reads to improve the quality of the reads. Then align-
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ment is done using burrows-wheeler aligner (BWA) with a reference genome. Then
Freebayes or GATK based variant caller is used to identify the variants of mutations.
Finally, the functional annotation is done using existing variant dataset. Then further
downstream analysis, for example, gene enrichment analysis, protein-protein interac-
tion and gene pathway analysis can be done using a variety of web tools like DAVID,
KEGG and gene ontology (GO). By doing this analysis, it is possible to know the
exact chromosome location of variants and its corresponding gene which is responsible
for that variation.
2.3.4 Gene Ontology and Pathway analysis
Gene ontology analysis is useful for finding out if a set of genes are associated with
a specific biological process, cellular component or molecular function [34]. Perform-
ing this analysis is the core step to extract any meaning from the result. GO provides
a set of structure in annotating genes and GO terms, with a name, a unique alphanu-
meric identifier, a definition with cited sources, and a namespace with the domain
where it belongs. Gene Ontology covers three domains: i) cellular component, the
parts of a cell or its extracellular environment. Ii) molecular function, the elemental
activities of a gene product at the molecular level, such as binding or catalysis iii) bi-
ological process, pertinent to the functioning of integrated living units: cells, tissues,
organs, and organisms. On the other hand, A biological pathway is a sequence of
interactions between molecules in a cell that results in a certain product of changes
in a cell. Those interactions aim to control the flow of information, energy and bio-
chemical compounds in the cell and the ability of the cell to change its behaviour
in response to stimuli. There are several types of biological pathways with the most
commonly known ones being metabolic, signalling and gene-regulation pathways. By
comparing two pathways, researchers can find what triggered such disease. This gene
enrichment and pathway analysis and can be performed using various tools, for in-
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stance, DAVID, PANTHER9, or gProfiler11.
In the literature review, artificial intelligence and its applications in the bioinfor-
matics field are well studied in order to classify disease subtypes and to find novel
biomarkers.
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Chapter 3
Feature Extraction using Adversarial Autoencoder
3.1 Overview
Breast cancer is a common and debilitating disease affecting mainly women around
the world. According to cancer Australia, 17730 new cases diagnosed in 2017 and
there were 3114 death from breast cancer however five-year relative survival rate
had increased from 72% to 90% in between 1982 to 2012 [35]. There are several
molecular subtypes of breast cancer such as luminal A (LumA), luminal B (LumB),
triple-negative (Tri-Neg), HER2 enriched and Claudin-Low. Also, breast cancer can
be classified by its histological types such as ductal carcinoma, lobular carcinoma
or mixed carcinoma. Furthermore, there are multiple pathological stages of breast
cancer such as stage 0, I, II, III and IV. However, genetic data is highly correlated
with molecular subtypes. It, is important to note that inherited genetic mutation can
greatly increase the risk of developing cancer, therefore analysing genetic subtypes
can help us to detect cancer at the early stages and increase five-year survival rate.
Besides, the gene expression profile enables cancer diagnosis and treatment of tumour
characterisation in order to minimise the recurrence [36]. Although mammography
remains the mainstay of a breast cancer diagnosis with fewer false-positives, gene
expression data can reveal the root cause of cancer by analysing RNA expression,
mutation and methylation patterns [37] [38] [39].
Machine intelligence methods automatically detect the pattern of data and measure
predictive targets based on its learning. Vanishing gradient, overfitting and comput-
ing power were some of the limitations of artificial neural network (ANN) ever since
it was introduced [40]. However, enhanced computing power with graphical pro-
cessing units (GPUs) and advanced algorithm, for example, MLP, recurrent neural
network (RNN), convolutional neural network (CNN), autoencoder etc. exhibited sig-
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nificant performance to overcome those challenges. Machine intelligence has brought
a paradigm shift to health care, and CAD to facilitate radiologist to reduce assess-
ment time and increase detection accuracy [40]. Computational biology has already
shown promising results in medical imaging, however analysing genomics, and tran-
scriptional profiling data is more challenging because of its high dimensionality, small
sample size, and missing values. Deep learning which is a part of machine intelligence
can extract high-level features in an unsupervised manner and find complex patterns
on unseen data.
3.2 Challenges
Gene expression data of RNA-Seq are quite big and need a proper analysis tool
to classify and extract biological information. Medical data has lots of issues such
as missing values, low quality data, small sample set size and higher dimension all
of which create noise in the data. To remove noises, proper pre-processing steps are
required that will help the classifiers to classify diseases more efficiently.
The first challenge comes with higher dimensionality of the available datasets. This
high dimension and sparseness of data often lead to overfitting. This problem can be
handled by applying various dimensionality reduction methods such as autoencoder
which improves the classification performance.
Among thousands of genes, only a few of them are relevant and contain useful infor-
mation thus extracting biologically essential genes are extremely important. However,
it is challenging to extract relevant genes from encoded data. First, it is needed to
analyse the weight matrix of a neural network then sort out highly weighted genes.
If neural network has any hidden layer, it is required to compute the dot product of
the weight metrics for each layer. By extracting highly weighted genes give biologists
key insights on how those genes are correlated to a specific type of cancer.
Furthermore, classes in a dataset are not equal in number which gives a biased result
during model evaluation. Most machine learning and neural network based algo-
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rithms are not designed to deal with such imbalanced classes. Also, it is difficult to
train a deep learning model with a small number of samples. Therefore, the sample
size needs to be increased, and classes need to be balanced using over-sampling tech-
niques. Most importantly, high computational power with GPU cluster is required
to get the results in an acceptable time. In short, sophisticated pre-processing steps
and high-end computational resources are needed to analyse the genetic data.
3.3 Data Collection
Two public data-sets from cBioportal1 were used in this work. First, data-set is
breast invasive carcinoma (TCGA, Cell 2015) shortly named as BRCA has five molec-
ular subtypes such as LumA, LumB, Basal, Trig-Neg and Her2. However, Basal and
Tri-Neg sample are merged together as they share very similar biological pattern [41].
This data-set contains 20439 genes and 605 number of patients. Then, a different
cancer data-set was chosen which is uterine corpus endometrial carcinoma (TCGA,
Nature 2013), shortly named as UCEC and categorise them into four molecular sub-
types for example copy number high (CNH), copy number low (CNL), hyper-mutated
(HYM) and ultra-mutated (ULM). UCEC contains a total number of 230 samples and
each sample has 15482 genes. The data was labelled with their corresponding clinical
information.
The main goal of this work is to present a new approach for dimensionality reduction
using AAE and evaluate its performance in two ways. First, extracted features will
be evaluated through supervised classification using twelve different classifiers. Then
to verify AAE’s capability, biologically relevant genes will be extracted using the
connectivity metrics of its possible space and compared with other state-of-the-art
methods.
1cBioportal http://www.cbioportal.org/
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3.4 Evaluating Performance of AAE using Classification
3.4.1 Background
Several promising studies have attempted to classify and cluster gene expression
using various machine learning algorithms. Unsupervised deep feature extraction al-
gorithm such as stacked denoising auto-encoder (SDAE) and variational auto-encoder
(VAE) has been applied to extract the features [37] [42] [43]. Moreover, it has
been compared with traditional machine learning algorithm based method such as
principal component analysis (PCA) with different kernels to measure the perfor-
mance [37] [43] [44]. These techniques can also be applied to predict protein-protein
interaction and discover new drugs. Various unsupervised clustering algorithm includ-
ing partition based clustering for evaluation, K-means clustering, hierarchical clus-
tering, expectation maximisation (EM) and non-negative matrix factorisation (NMF)
clustering algorithm have been applied to cluster the gene [45].
Also, to extracting the features, ANN and deep belief network (DBN) have been
employed to classify the diseases [46] [47]. Moreover, various machine learning algo-
rithm such as multinominal logistic regression (LR), DT, SVM, random forest (RF)
etc. equally exploited in cancer research in order to classify diseases from microarray
and RNA-Seq data [37] [42] [44] [46] [48].
As discussed prior, a high number of genes with limited number of patients intro-
duces a significant amount of noise which is known as the “curse of dimensionality”.
To overcome this challenge feature extraction method such as AAE has been pro-
posed [49]. This technique also facilitates to visualise high dimensional data and
prevents manifold fracturing problem [49]. To evaluate the effectiveness of extracted
features through AAE (see Algorithm 2), twelve different supervised classifiers are
used such as MLP, RF, SVM, KNN, DT, XGB, QDA, LR, gradiant boosting (GB),
gaussian naive bayes (NB), linear discriminative analysis (LDA) and voting classifier
(VC).
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3.4.2 Methodology
Data Pre-processing
Class imbalance often leads to overfitting and low predictive score [50]. Since the
chosen data is highly imbalanced in nature, synthetic minority oversampling technique
(SMOTE) is adapted to balance the classes. Next, normalisation is used to eliminate
data redundancy and noise. In this project, the use of quantile transformer (QT)
normalisation technique which transforms the features to follow a uniform or a normal
distribution was used [51]. This technique not only reduces the impact of outliers but
also spread out the most frequent values.
Dimension Reduction
After using a feature selection method, unsupervised AAE depicted in Fig. 3.1
is used to reduce the dimensionality. This state of the art auto-encoder encodes the
data into a given dimension without losing significant gene pattern. The training
process of AAE is unsupervised thus label is not necessary. However, this AAE needs
huge data to capitalise its ability for feature extraction.
Evolutionary Approach for Classification
Applying deep learning model to any data takes a significant amount of time and
effort to get optimal hyperparameters. Therefore, TPOT [52] library was used for
finding optimal hyperparameters of twelve classifiers. However, it is needed to select
some parameters of the genetic algorithm (GA) such as generations, populations
etc. to evolve the model. Advantages of GA is that it has a much less number of
parameters compared to deep learning method. In addition, it finds the best deep
learning parameters based on its fitness function. Here, ‘accuracy’ is chosen as a
fitness function. The limitation of this tool is it only able to search for the scikit-
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learn based classifier and regressors model and optimise their parameters. In the
experiment, TOPT generated hyperparameters are used.
Discriminator
z
Real or 
Fake?
Weight Optimization
Latent Space
GeneratorEncoder
Multiclass
Classier
Input RNA-Seq Data
PLumA
PLumB
PBasal & Tri-Neg
PHER2-enriched
605 x 20439
Fig. 3.1. Architecture of AAE for classifying cancer subtypes.
3.4.3 AAE model implementation
Four different autoencoders such as AE, AAE, VAE, and denoising autoencoder
(DAE) were used in this work. Unlike other autoencoders, the proposed AAE archi-
tecture consists of three networks such as an encoder, generator, and discriminator.
The additional discriminator network further compares the generated result with ac-
tual input and update the weight of each network. First, single layer AAE, that is,
an autoencoder without a hidden layer, having the input directly connected to the
output, was used to reduce the features into 50 and classifiers were used to validate
the result, but results were not promising. Therefore, AAE architecture having one
hidden layer in each network is used as described in Table 3.1. Encoder network
contains an input layer which takes all genes (20439) as an input, one hidden layer
with 1000 neurons and an output layer with 50 neurons. Next, generator network
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contains an encoded vector (50) as input, one hidden layer with 1000 neurons and
generate fake genes (20439) as output. Finally, discriminator network takes an actual
gene and generated gene as input and contains one hidden layer with 1000 neurons
and one neuron in the output. During pre-training of this model, adadelta is used
as an optimizer with a learning rate of 1 and binary cross entropy is used as a loss
function. In addition, 100 epochs are used with batch size of 128 to train the model
in an unsupervised manner. After that, fine-tuning of encoder network is performed
using an additional layer having four neurons with softmax activation function. The
fine tuning training process is supervised and allow output layer of encoder (50 neu-
rons) to optimise its weights. Validation of the model was performed using twelve
different classifiers. The use of dropout or regularizer was avoided. The number of
hidden layers are further increased, and the result appears that increasing the depth
of the model modestly improves the performance.
3.4.4 Performance Metrics of Classification
The performance of a system is evaluated through a confusion matrix which helps
to find classified and mis-classified rate of the test data. The classification perfor-
mance is measured using various metrics like accuracy, sensitivity, specificity, preci-
sion, f-score, the area under the ROC curve (AUC) and the Matthews correlation
coefficient (MCC). Accuracy is defined as ratio of properly classified data to overall
classified data. The accuracy is shown in Eq.3.1.
Accuracy =
TP + TN
TP + FP + TN + FN
(3.1)
Sensitivity is measured as the proportion of correct positive (cancer) prediction with
the total number of positives. For example, if the system is highly sensitive and test
result is positive, it is certain that patient does have disease(or cancer). It can be
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calculated using Eq.3.2.
Sensitivity (True positive rate or Recall) =
TP
TP + FN
(3.2)
Specificity is calculated as the ratio of correct negative prediction (not cancer)
divided by total number of negatives.
Specificity (True negative rate) =
TN
TN + FP
(3.3)
Precision is defined as number of correct positive prediction divided by sum of
true positive and false positives.
Precision =
TP
TP + FP
(3.4)
F1-score of a system is referred to as the harmonic mean of precision and recall
that is:
F1− Score = 2× Precision×Recall
Precision+Recall
(3.5)
MCC also known as phi coefficient takes account confusion matrix parameters and
does consider imbalance classes in the data. Furthermore, this method can be used
in both binary and multi-class classification.
MCC (Multicalss) =
c× s−∑Kk pk × tk√
(s2 −∑Kk p2k)× (s2 −∑Kk t2k) (3.6)
Kappa score measures the level of agreement between two annotators on a classifi-
cation problem. Kappa score takes account the possibility of the agreement occurring
by chance. It is defined as follows:
KappaScore(κ) = (po − pe)/(1− pe) (3.7)
where,
TP=True Positive
TN=True Negative
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FP=False Positive
FN=False Negative
C=Confusion Matrix
tk =
∑K
i Cik, the number of times class k truly occurred,
pk =
∑K
i Cki, the number of times class k was predicted,
c =
∑K
k Ckk, the total number of samples correctly predicted,
s =
∑K
i
∑K
j Cij, the total number of samples.
po = The observed agreement ratio
pe = Expected agreement
Table 3.1.
Summary of proposed AAE architecture. Each of the network in AAE
contains one hidden layer with 1000 neurons. To train the model, adadelta
optimizer is used with learning rate of 1 and binary cross entropy is used
as a loss function.
Network Input Ouput Layer Activation Optimizer Loss
Encoder All genes actual Encoded vector
1st Tanh
Adadelta Binary crossentropy
2nd Tanh
Generator Encoded vector All genes generated
1st Tanh
2nd Sigmoid
Discriminator
All genes actual &
Discriminator probability
1st Tanh
All genes generated 2nd Sigmoid
3.4.5 Results
Experimental result presented in Table B.2 shows twelve classifiers such as DT,
GB, KNN, LDA, LR, MLP, NB, QDA, RF, SVC, VC and XGB are used to evalu-
ate various feature extraction techniques such as AAE, PCA, VAE, AE and DAE in
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terms of accuracy, recall, precision, f1-score, AUC, MCC and kappa score. All the
experiments were performed using five-fold cross-validation and StratifiedKFold tech-
niques were adopted. In BRCA dataset, four breast cancer subtypes such as LumA,
LumB, Tri-Neg & Basal, and Her2 are labelled from the clinical information of the
patients. Therefore, predicting breast cancer subtypes is a multiclass classification
problem. However, the dataset contains 20439 genes which need to be reduced in
order to classify correctly.
[a]
[b]
Fig. 3.2. Various classifiers such as DT, GB, KNN etc. are used to evaluate
the performance of feature extraction methods such as AAE, PCA, AE,
VAE and DAE. (a) Precision score is compared among feature extraction
methods using twelve different classifiers. (b) Recall score is compared
among feature extraction methods using twelve different classifiers.
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Fig. 3.3. Performance of various feature extracting methods in terms of
their computation time.
As the dataset is growing fast, an efficient feature extraction technique is necessary
which can handle big amount of data and can perform well on any classifier. Therefore,
AAE based feature extraction algorithm is developed which performs well on any
classifier in terms of all the performance metrics. For this, current state-of-the-art
methods such as PCA, VAE, AE, and DAE are used to compare the results. It
is found that AAE is most steady across all classifiers. In the experiment, highest
of 86.44% accuracy, 86.01% f1-score, 86.44% recall, 86.78% precision, 97.19% AUC,
0.79 MCC, and 0.78 kappa score are obtained when using MLP classifier with PCA
based feature extraction method. In addition, PCA with DT, KNN, NB, QDA, SVC
and XGB shows precision of 75.41%, 79.89%, 70.56%, 72.25%, 25.25% and 81.80%
respectively. However, AAE based method with DT, KNN, NB, QDA, SVC, and
XGB classifiers shows performance improvement in precision having a score of 84.41%,
85.74%, 85.42%, 84.27%, 85.96% and 85.47 respectively. Fig. 3.2 shows precision and
recall score of twelve different classifiers where AAE found to be mostly steady. To
summarise, six out of twelve classifiers such as DT, KNN, QDA, SVM, NB, and XGB
perform well in all performance metrics when using AAE as a feature extraction
method. Remaining six classifiers such as GB, LDA, LR, RF, VC and MLP with
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AAE perform almost similar or slightly lower compared to other feature extraction
methods. Here, AAE takes 2164 MB of memory and 10 min 54 sec for training, fine
tuning and classifying various cancer sub types as depicted in Table. B.3.
Fig. 3.4. Proposed AAE is compared with other methods in terms of seven
performance metrics such as accuracy, F1-score, recall, precision, AUC,
MCC and Kappa.
3.4.6 Discussion
In this work, AAE based feature extraction method is essential in extracting rel-
evant information in both microarray and RNA-seq data. Based on the results, it
is observed that the proposed model yields satisfactory results in classification that
outperforms traditional methods such as PCA, AE, VAE and DAE. AAE is trained in
an unsupervised manner to extract highly correlated genes and see how well various
classifiers can predict cancer based on those features. In this study, pre-processing
step which includes sampling, normalisation and feature extraction are essential part
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for classification. Then comparison among various feature extraction methods are
made based on the performance of twelve different classifiers which are widely used
for cancer prediction. Results using BRCA dataset shows that AAE feature extrac-
tion method leads to better performance on most of the classifiers compared to other
techniques such as PCA, DAE, AE and VAE. Most importantly, AAE provides consis-
tent results (see Fig. 3.4) in all performance metrics across twelve different classifiers
which makes this feature extraction model classifier independent. In terms of compu-
tation time and memory usage, PCA takes less time and memory among all; however,
my proposed AAE performs best compared to other existing neural network based
autoencoder (see Fig. 3.3). The limitation of this architecture is that it requires large
amount of data to extract meaningful features. It is anticipated that larger dataset
has the potential to take advantage of the power of the deep neural network to extract
the gene expression.
3.5 Evaluating Performance of AAE by Analyzing Connectivity Matrices
3.5.1 Overview
High throughput genomics in combination with machine learning give opportunity
to the researchers to identify disease-associated genes from a large dataset which is
essential for understanding underlying biological mechanisms.
The growth of transcriptome datasets provide further opportunities to identify novel
biomarkers that are likely to facilitate drug development, targeted therapy, and pro-
vide direction in clinical research. Gene selection is essential because focusing on the
marker genes can reduce the cost of biological experiment and decision. With the
advent of NGS technologies, modern deep learning algorithms try to figure out fun-
damental biological questions such as prediction of single nucleotide polymorphisms
(SNPs) [53], identification of biologically relevant gene [54] [55] [56], design of pro-
tein [57] and prediction its structures [58] [59]. In addition, personalized treatment
such as targeted therapies, and predicting drug response could disrupt the traditional
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treatment in future [60].
Feature extraction, an essential part of data analysis is used to reduce high-dimensional
data into an amenable number of features which is helpful to interpret results. In
addition, feature extraction methods in cancer genomics are able to identify small
list of biomarkers with potential clinical utility. The application of feature extrac-
tion methods is particularly relevant for transcriptomic datasets that often have very
large features. Many researchers have applied unsupervised deep learning models
such as VAE [54] [61], and DAE [55] in transcriptomic datasets to extract meaning-
ful representations of gene modules. Moreover, analysing the hidden nodes within
neural networks could potentially highlight important genetic behavior [62]. Latent
space features learned through unsupervised pre-training and supervised fine-tuning
can reveal underlying patterns in genomic and biomedical domains. DAE is applied
on RNA-Seq data from the cancer genome atlas (TCGA) database and used latent
space to identify genes that are critical for the diagnosis of breast cancer. Similarly,
VAE applied on pan-cancer gene expression data and compared with other feature
extraction algorithms, however VAE proved to be more informative.
Due to low sequencing cost, sample size keep increasing thus deep learning based
models are becoming even more successful. In contrast, traditional analysis methods
cannot cope up with large dataset and often produced biased results. Furthermore,
unsupervised feature extraction methods are currently less developed, poorly under-
stood and difficult to train [63] than supervised counterparts, however it has huge
potential in extracting genes that bear significant biological relevance.
In this work, a neural network based feature extraction model is presented using gene
expression data that identifies biologically relevant genes and their functions. The
examination of these genes could be useful in validating recent discoveries in cancer
research. Proposed model has enhanced the performance of selecting relevant genes
compared to current state-of-the-art methods. A list of highly weighted genes is first
selected then sorted out in descending order. The studies include identification of
genes responsible for diseases, functional annotation of genes, and the analysis of
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gene signaling pathways from biological databases. Experiments are conducted in or-
der to compare the proposed methods with current state-of-the-art methods in terms
of biological significance, and showed the efficacy and potential of the proposed ap-
proach with promising results.
3.5.2 Methodology
Neural network based AAE model is introduced to extract biologically-relevant
features from RNA-Seq data. A method named TopGene is also developed to find
highly interactive genes from the latent space. AAE in combination with TopGene
method finds important genes which could be useful for finding cancer biomarkers
(see Fig. 3.5).
Data Pre-processing
Class imbalance often leads to overfitting and low predictive score [50] there-
fore synthetic minority oversampling technique (SMOTE) is adopted to balance the
classes. Quantile transformer normalisation technique is used to eliminate data re-
dundancy and noise.
Dimension Reduction
After data prepossessing, AAE model is trained to reduce the data into a smaller
dimension without losing significant gene pattern. Hyperparameters of AAE model
such as batch size, epochs, optimiser, learning rate and loss function are chosen using
grid search technique to obtain the lowest train and validation loss. The training
process of this autoencoder is unsupervised thus label is not necessary. Finally, AAE
generated features are compared with existing state-of-the-art methods such as AE,
DAE, VAE, ICA, NMF and PCA.
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Fig. 3.5. Block diagram for weight matrix analysis using AAE architec-
ture.
Sorting Highly Weighted Genes
Trained AAE generates low dimensional latent space which is then sorted using
TopGene method. When AAE has hidden layer, it is needed to do dot matrix mul-
tiplication among different layers to obtain final weight. On the other hand, single
layer AAE does not have any hidden layer; hence dot matrix multiplication is not
needed. TopGene method is then applied to sum up the weight across all the nodes.
Then gene is sorted according to their weights, and top 50 genes are taken for further
analysis.
GO and Pathway Analysis
Functional enrichment of top 50 highly weighted genes through GO analysis are
examined using DAVID tools. Table 1 presents statistically enriched GO terms under
’molecular function’, and corresponding p-value is shown. Many of the most signifi-
cant terms are related to olfactory receptor activity. It is observed that top 50 genes
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and olfactory receptor activity is found to be tumour suppressor for breast cancer.
Pathway analysis is also used for identifying related proteins and genes. It gives
various interactions among molecules in a cell related to its metabolism, gene regu-
lation and signal transmission [64]. DAVID pathway [65] [66] was used for retrieval
of pathways associated with genes identified from the present study. Also, olfactory
transduction is found as a pathway shows in Figure C.1 for breast cancer.
3.5.3 AAE model Implementation
AAE is trained in two phases with stochastic gradient descent (SGD) algorithm
[67]. First, encoder encodes the data and generators acts like decoder which repro-
duces the data as close as possible to its input and tries to minimise the reconstruction
error. Second, discriminator network tries to tell apart the generated sample from the
original sample (actual input) then update the weights of generator and encoder [67].
Once the training process is done latent space z contains useful biological information
by omitting noisy features. AAE is versatile and powerful as it can extract both
linear and nonlinear relationship from the input data. First, single layer AAE, that
is, an autoencoder without hidden layer, having the input directly connected to the
output, was used to reduce the features into dimension of 50 then its weight matrix
was analyzed to know its biological context. In addition, AAE with one hidden layer
with 1000 neurons in each network (encoder, generator, and discriminator) is tested
and it reveals meaningful genes. During training the network, adadelta is chosen as a
optimizer with learning rate of 1 and binary cross entropy is used as a loss function.
In addition, 100 epochs are used with batch size of 128 to train the model in unsuper-
vised manner. After that weight matrix is analyzed to sort out highly weighted gene.
In this model, dropout or regularizer was not used as validation loss and training loss
were almost similar. The number of hidden layers further increased, however result
appears that increasing the depth of the model modestly improves the performance.
For the implementation of this model, scikit-learn library [51] [68] and keras API [69]
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with tensorflow [70] back-end are used which was running on computer specified on
Table B.1. AAE encoded latent space contains important subsets of genes effective
for cancer detection. For a single layer, weight matrix is considered as W = G × 50
where G in the number of genes and each gene contains 50 nodes. Deeper model is
also analyzed, where dot product of the weight matrix is calculated for each layer of
AAE. For example, 2 layer neural network having one hidden layer with 1000 neu-
rons, weight matrix of first layer is W1 = GX1000 and second layer is W2 = 1000X50.
Then applying dot product W = (W1.W2) finally got, W = G× 50. Therefore, it can
be generalised that weight matrix for the n-layer neural network as
W =
n∏
i=1
Wi
It is found that the weight matrix was strongly normally distributed Fig 3.6. First, all
the nodes for each gene are summed up then sorted out genes by its weight. Method
of sorting out weight is explained in Algorithm 1. Finally, those genes are analysed
by doing GO and pathway analysis to know its biological insights.
3.5.4 Results
All experiments in this study were conducted on University’s server described
in Table B.1. Experimental result using BRCA data presented in Table 3.2 and
Table B.5 and validated result using UCEC data presented in Table B.6. In this
experiment, causation of the diseases are explored by extracting highly weighted
genes form the latent space. By analysing those genes could help us to find out
the cause of the diseases. Here, top 50 highly weighted genes are taken for further
GO and pathway analysis. In the proposed model, four genes such as OR2T27,
OR2A25, OR8B8, OR6V1 are found that are related to olfactory receptor activity.
In addition, those four genes provide olfactory transduction pathway. In a recent
study by Lea et al. (2018) shows that the olfactory receptor genes such as OR2B6
are highly expressed in breast carcinoma tissues compared to the respective healthy
tissues [71]. They considered OR2B6 as a potential biomarker for breast carcinoma
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Table 3.2.
Results of Gene enrichment analysis using various feature extraction meth-
ods on BRCA cancer data-set.
Algorithm Molecular Function P-value
AAE (Single layer) Olfactory receptor activity 5.92e-2
AAE (2 layer) Small conjugating protein ligase activity 7.34e-2
AAE (3 layer) Single-stranded RNA binding 6.25e-2
AE General RNA polymerase II transcription factor activity 7.97e-3
DAE Not Available
PCA Calcium ion binding 6.44e-2
VAE General RNA polymerase II transcription factor activity 9.55e 2
NMF Transition metal ion binding 2.8e-2
ICA RNA helicase activity 6.49e-2
tissues. Their result provides validation of the proposed model. Deeper model of AAE
(2 layers) identified protein ligase activity which is closely linked with human breast
cancer [72]. PCA extracted genes has GO terms related to calcium ion binding which
is known to be associated with breast cancer [73] [74]. Choon et al. (2018) found
that transporting calcium ions into milk also have altered expression in some breast
cancers. ICA generates molecular function related to RNA helicase activity which is
associated with breast cancer. RNA helicase plays an oncogenic role in breast cancer
by changing the cell cycle [75]. Other feature extractor methods are also applied
and analysed their highly weighted genes but no molecular function or significant
pathway is found to be associated with breast cancer. In terms of computational
efficiency, my proposed single layer AAE takes 1946 MB of memory and 1 min 13 sec
of computation time (wall clock) as described in Table. B.4. Furthermore, proposed
methods are evaluated with different data-set named UCEC which contains four major
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Fig. 3.6. Histogram of AAE weights after applying TopGene algorithm.
subtypes of endometrial carcinoma. Single layer AAE model identified metal ion
binding genes such as KLF6, EGR3, CLTB, BRSK2, ZSWIM7, ZNF655, TKTL1,
BBOX1, ZNF677, RNF114, PHF2, SLU7, ALOX5, CPD, BMPR1B, CACNA1A
which is associated with endometrial cancer risk [76] [77]. It is considered that heavy
metal like cadmium are well known carcinogens and can increase the incidence of
endometrial cancer [77]. It is observed that genes extracted by other methods such
as PCA, VAE, NMF, AE do not have relevance with the diseases.
3.5.5 Discussion
In this work, AAE based feature extraction method is presented. It is shown
that feature extraction methods not only help classification or visualise data, it is
also essential in extracting relevant biological information from both microarray and
RNA-seq data. Based on the results, it is observed that the proposed AAE model
provide unique benefit in identifying biomarker on two independent data-set. Using
BRCA data-set, only AAE based model find important pathway for breast cancer
identification. AAE with 2-layer neural network also extracts useful genes for tumour
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identification. Single-cell RNA-Seq, long read RNA-seq and microbiome datasets
has massive amount of data; therefore deep learning based AAE model has a great
future. The performance of the AAE model could certainly improve visualisation
of high dimensional data as it provides the non-linear mapping. In the future, it is
anticipated that unsupervised AAE can provide a new way to extract and integrate
large genomic data-set effectively.
3.6 Chapter Summary
This chapter presents applications of AAE extracted features for classification
and for identifying biologically relevant genes. Proposed method exhibited high per-
formance on multi-class classification irrespective of the classifier. Also, single layer
and 2-layer AAE performs best in extracting meaningful features. It is successfully
shown that AAE has captured important information in the latent space and has
identified potential bio-marker by analysing the weight matrix. The most optimal
hyper-parameters were determined for the AAE model and then evaluated the results
using fivefold cross-validator. As data-set is growing exponentially, in the future, it
is possible to develop higher capacity model with multiple hidden layers to identify
cross-cancer bio-markers using heterogeneous cancer data. To sum up, AAE based
feature extraction method reveals important bio-marker that could be used in fore-
casting diseases progression and determining treatment strategy. In the next chapter,
instead of using normalized RNA-Seq data, raw methylated DNA data is used in order
to find novel biomarkers; hence a pipeline is proposed.
42
Chapter 4
Identification of Novel Mutation using
Bioinformatics Pipelines
4.1 Overview
When hematopoietic cells proliferate abnormally, it leads to the development of
leukemia. World health organization (WHO) incorporated genetic information into
the diagnostic algorithms [78]. In their revised report, genetic test was reinforced
for AML classification. It also emphasises on genetic test to define entities which
are clinically relevant to AML in conjunction with immune-phenotype, clinicopatho-
logic features and morphology [79]. Due to continuing advancement, the application
of high-throughput genetic technologies, such as NGS and gene expression profiling
revealed new potential therapeutic targets and mechanisms of tumorigenesis [80].
Leukemia is recognized as one of the major causes of morbidity and mortality among
children and adults in the world. It is estimated that leukemia accounts for 2.5% of
cancers worldwide and approximately 250000 people are diagnosed every year [81].
Another type of leukemia includes CML, which affects the adults more than children.
The CML affects the myeloid cells which produce red blood cells (RBC), white blood
cells (WBC) and platelets. The change in this stage causes the formation of an ab-
normal gene which is responsible for CML. The myeloid cells then grow, divide and
build up in the bone marrow and then transport to other parts of the body through
blood. AML can be divided into acute and chronic leukemia and further leading
to AML which is one of the most common leukemia among adults affecting ∼80%
of cases. It also affects ∼20% of cases in children [82]. It has been observed that
the pathogenicity of AML in most patients are linked to oncogenic fusion proteins
which are generated due to chromosome translocation or inversion. When a gene
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ontology profile of 1,100 known genes studied, it revealed that each translocation was
responsible for altering a specific function such as regulation of transcription, cell
cycle, protein synthesis, and apoptosis [83]. Traditionally the risk was calculated by
cytogenetic studies, but molecular detection of gene mutations has also become im-
portant. As AML is heterogeneous, multiple genes are involved in the disease, and it
makes harder to treat [84]. About 749 chromosomal aberrations have been observed
in AML which includes oncogenes as well as loss of tumour-suppressing genes. It has
been noticed that abnormalities in certain genes as well the gene expression profile
confer prognostic significance in adult AML patients [85]. Somatic mutations have
been found in several genes for AML that includes JAK2, KRAS2, FLT3, NUP98,
and KIT. The variant analysis is one of the significant applications of NGS technology
which provides genetic abnormalities. Several NGS analytical approaches are devel-
oped to identify somatic and germinal variants which focuses on selectively enriching
the region of interest from either whole genome or transcriptome or exome data files.
Hence, allowing widespread application in current research typically for molecular di-
agnostics purpose. In the current research, one of the applications of NGS technology
is focused, i.e. variant analysis for finding out novel variants which may be potent
carcinogens involved in leukemia.
4.2 Data Collection
The variant analysis was performed on methylated DNA samples where SRR408629
and SRR408630 were Leukemia cell line from AML patient. The other samples such as
SRR408623, SRR408624, SRR408625, SRR408626, SRR408627 and SRR408628 were
reprogrammed cell line. The samples were collected from the European Nucleotide
Archive (ENA) with study accession no. PRJNA156619 and the library layout was
single-end Illumina sequenced. The samples considered are as follows in the Table
4.1. Heretofore, the methylation pattern of k562 cell line was analysed, and epigenetic
change was investigated during the reprogramming process. The previous study also
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showed that epigenetic change had functional consequences on leukemia phenotype.
However, in this study, we analyzed methylated DNA of various leukemia cell line,
named k562, hES, LiPS1 and LiPS3 to find the mutations. In addition, mutation fre-
quencies are validated using DriverDB and Intogen databases in order to find novel
mutations. Finally, we reported the responsible genes for the mutations with their
chromosome location (see Table 4.2).
Table 4.1.
Eight leukemia data samples with their corresponding sample types are
described below.
Sample ID Sample Type
SRR408623 LiPS1 Cell line (Reprogrammed)
SRR408624 LiPS1 Cell line (Reprogrammed)
SRR408625 LiPS3 Cell line (Reprogrammed)
SRR408626 LiPS3 Cell line (Reprogrammed)
SRR408627 hES Cell line (Reprogrammed)
SRR408628 hES Cell line (Reprogrammed)
SRR408629 K562 Cell line (Leukemia Cell)
SRR408630 K562 Cell line (Leukemia Cell)
4.3 Methodology
The whole pipeline for variant analysis is depicted in Fig. 4.1. The analysis
was carried out using Galaxy which is a web-based server available for NGS data
analysis. The data can be uploaded directly through European nucleotide archive
(ENA), and FASTQ Groomer tool extracts this data into FASTQ formats. The
quality of this data checked through FASTQC which gives us detailed information
about the sample. The parameters include GC content, over-expressed sequences, per
base sequence quality and sequence length distribution. If the data has requires any
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further processing like trimming [86], then it is performed using either Trimmomatic
or FASTQ Trimmer. Trimming adapter sequences is necessary as it contaminates the
sequences. Trimmomatic, on the other hand, uses a sliding window method wherein
the bases are removed which are below the quality threshold, by scanning the entire
sequence [87] [88]. In the following experiment, the trimming was performed using
the tool Trim Galore which is specifically used for DNA-methylated samples. The
stringency and phred quality of base calls for adapter removal need to be specified
individually. Next, mapping was performed using Bowtie2 for longer read sequences.
It is an alignment algorithm used to align sequence reads against a large reference
genome. It automatically chooses between local and end-to-end alignments, support
paired-end reads and performs chimeric alignments. The tool can be used for a wide
range of sequence lengths, ranging from 70bp to a few megabases [89]. Then, variant
analysis is performed using three different variant callers such as Freebayes, GATK
and Deepvariant and choose the common variants among them as illustrated in Fig.
4.2. Freebayes is a variant detector used to find SNPs, insertion-deletion mutation
(Indels) and multi-nucleotide polymorphisms (MNPs) [90]. Here, DeepVariant is a
deep neural network based tool that was used to call genetic variants from next-
generation DNA sequencing data [53]. Next, variants were annotated using VEP [91]
which is an annotation server that can annotate SNPs, Indels and even MNP’s. After
annotation, low quality synonymous genes are filtered out and novel variants are
found. Finally, GO, and protein-protein interaction (PPI) was performed on variant
genes to know their biological function and how those genes are connected.
4.4 Results & Discussion
Genes such as KIT, JAK2 or KRAS2 are well known to be involved, but regarding
heterogeneous nature of AML many other genes may also be involved that are not
known yet. After applying pre-processing steps, variant caller is used to find the vari-
ants. Through the process of variant calling, the VCF files were obtained using VEP
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Fig. 4.1. In this block diagram, the whole pipeline for variant analysis
are shown. First, in the pre-processing steps quality of the data are ob-
served and trim the data to improve the quality. Then data is aligned
with reference human genome. Next, PCR duplicates are removed before
variant calling. Next, important variants are obtained through filtering.
After that, filtered variants are annotated with reference variant annota-
tion databases. Finally, data is further refined in order to find, validate
and visualize novel variant.
tool. Annotated files contained genes and their exonic functions. Then synonymous
SNVs and unknown SNVs are qualitatively filtered out since these types of mutations
do not have any significant effect on the genes exonic function. The remaining exonic
functions, i.e., non-synonymous SNVs, frameshift mutations, stop gain and stop loss
mutations were taken to obtain novel SNPs. The variants obtained from the analysis
are shown in the Table 4.2. Total of 22 new variants are found by analyzing the
methylated DNA datasets. The involvement of variants in AML was confirmed using
DriverDB database [92]. Their mutation frequency for AML was found using Intogen
Database [93]. Three variants such as ZFHX3, DOK2, and PKHD1 were found to
have some involvement in AML as observed on DriverDB. The rest of the genes were
novel and rarely associated with AML.
Welch et al. performed a study on the origin and evolution of genes involved in AML
and concluded saying that ZFHX3 was found to be mutated in patients [94]. ZFHX3
has been previously studied for acute lymphoblastic Leukemia by Oshima et al. [95],
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and the mutation frequency for this was 1.16%. In this study, the mutation frequency
of ZFHX3 in AML was found to be 0.51%. It was further observed that ZFHX3 was
involved in AML by a study conducted by Garg et. al. They conducted the profil-
ing of all somatic mutations observed in AML. ZFHX3 was reported as one of the
mutations in AML, but the chromosomal location was observed to be different [96].
Two non-synonymous mutations in ZFHX3 gene is identified at two different posi-
tions of chromosome 16. The gene DOK2 is responsible for downstream of tyrosine
kinase. The gene is found to have a mutation frequency of 0.51% for AML. The
involvement of this gene in AML is still mostly unknown. A study performed by He
et al. using RQ-PCR to detect the expression of DOK2 in AML patients confirmed
that decreased expressions of DOK2 and hypermethylation of their promoters could
be adverse in AML [97]. In another study performed by Kim et al. they found no
sign of DOK2 gene in AML. They concluded saying that DOK2 might be mutated
in other ways such as loss or gain of function or deletion of the locus. Research also
shows that DOK genes might be responsible for AML [98]. In this study, a non-
synonymous SNV of DOK2 on chromosome 18 is also found. The third gene showing
some previous expression in AML is PKHD1. A single SNV of textitPKHD1 gene
is found on chromosome 6. The mutation rate of PKHD1 was found to be 0.51%.
Also, PKHD1 is found to have relation with autosomal-recessive polycystic kidney
disease. Siraj et al. found that PKHD1 gene had a role in pancreatic ductal adeno-
carcinoma, but no reports on the expression in AML [99]. The other variants found
were non-carcinogenic or didnt have any role in AML. Their mutation frequency was
0%. Most of the variants are either less studied or not looked upon in perspective of
AML. Dillon et al. [100] conducted a study on recurrently mutated genes and their
role in AML patients. The patients were African, African Caribbean and of Japanese
origin. The study revealed that there were mutations across several pathways and the
genes involved in them. One of the pathways affected was NOTCH which contains
the MAMLD1 gene. The mutation was observed across all patients in the study. In
our study, we also found MAMLD1 mutation illustrated in Fig. ??. Bullinger Valk
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Fig. 4.2. Three different variant calling tools are shown in venn diagram
for sample SRR40862 & SRR408630.
conducted a study which consisted of profiling gene expressions involved in AML.
Multiple genes were studied involved in AML using multiple patients. Genes belong-
ing to HOX family and MYB were found to be expressed higher in many patients.
One of the genes DMWD involved in the study was found to be expressed but only
in a few numbers of patients [101]. When a study was performed on ovarian cancer
cells by Liu et al., it included CDK11 gene silencing by synthetic siRNAs or lentiviral
shRNA. It has been seen that CDK11 is essential in cell migration and invasion.
When a knockdown version of CDK11 by CRISPR-RNAi technology was used
for the study, it showed growth inhibitions in AML cells [102]. SLC or solute carrier
proteins are responsible for the transport of a wide range of substrates. SLC gene
and SLC2A5 was found to be expressed more in AML patients in a study conducted
by Chen et. al. Further, when a knockdown of the gene was introduced in AML cells,
it decreased cell proliferation, and overexpression of the same increased proliferation,
cell growth, migration, invasiveness. They also observed that AML cells utilise much
fructose under low-glucose conditions which are increased by SLC2A5 [103]. In a
similar study performed by Weng et al., studied the effects of SLC2A5 gene on lung
adenocarcinoma; they even did tests on AML cells and found similar results and
concluded by saying that AML cells largely take up fructose for cell proliferation and
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SLC2A5 gene assists in the uptake. They also used a knockdown of a gene which
showed less proliferation and decreased uptake of fructose [104].
The other SLC gene involved was SLC22A6 which acts as a transporter for anti-
cancer agents into cancer cells. It also helps in the uptake of various essential nutrients
required for the growth of cancer cells. Li Shu studied the same with various SLC
genes. They observed that specific genes were responsible for transporting anticancer
drugs to AML cells. They saw that mutation in such genes could be adverse for
patients with cancer [105]. No other particular study was found related to the role of
SLC22A6 in AML, and the effects are still unknown. Splicing factors or SF genes, one
such SF1 was observed in this study as well as a study conducted by Larsson et al.,
wherein, they studied different recurrent somatic mutations in various genes. They
observed that mutations rarely occurred in SF1 gene as compared to other genes and
further disregarded that there will be any effects of SF1 on AML [106]. EGR2 was
studied by Pospisil et al. where they consider the inhibition of oncogenic miRNA
cluster 17∼92 by EGR2.
It was observed that in most AML patients the levels of EGR2 were significantly
low as compared to the healthy counterpart. When EGR2 found into AML cells, it
was observed that inhibition of miRNA 17∼92 clusters involved in AML and were
overexpressed in the patients. Upregulation of EGR2 also led to induction of apopto-
sis by increasing the level of BIM mRNA [107]. Tian et al., also conducted studies on
EGR genes but focused mainly on EGR1. They did conclude that EGR1 was more
probable in causing AML than other EGR genes including EGR2. They also stated
that all members of EGR family share highly conserved DNA binding domain [108].
Plks or Polo-like kinases belong to serine-threonine kinases family which are respon-
sible for regulation of multiple intracellular processes like DNA replication, mitosis
or stress responses. Liu et al. conducted a study on Plks as a therapeutic approach
for cancer treatment. He et al. observed that PLK3 could be a possible tumour
suppressor gene because of the downregulation in many cancers. No specific relation
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Table 4.2.
List of novel variants obtained from annotated data
Sample ID Novel variants Type of mutations Chromosome Location
SRR408623 MAMLD1 non-synonymous ChrX: 150470758
SRR408624
SLC22A6 non-synonymous Chr11: 62983599
DMWD non-synonymous Chr19: 45786321
SRR408625
CDK11A non-synonymous Chr1: 1707539
SLC2A5 non-synonymous Chr1: 9037714
QSOX2 non-synonymous Chr9: 136226806
SRR408626 No novel variants are observed
SRR408627
EGR2 non-frameshift Substitution Chr10: 62813491
SF1 Stopgain Chr11: 64765966
ZFHX3
non-synonymous Chr16: 72796453
non-synonymous Chr16: 72796480
MYCBPAP non-synonymous Chr17: 50517594
DIRAS1 non-synonymous Chr19: 2717683
DOK2 non-synonymous Chr8: 21909724
SRR408628
PLK3 Stopgain Mutation Chr1: 44801922
GPR182 non-synonymous Chr12: 56996180
POU4F2 non-synonymous Chr4: 146639979
SRR408629
ATP13A2 non-synonymous Chr1: 16996279
TEX2
non-synonymous Chr17: 64214100
non-synonymous Chr17: 64214124
PKHD1 non-synonymous Chr6: 52053075
GTF3C5 nonframeshift Chr9: 133043843
SURF6 nonframeshift Chr9: 133332667
HECTD4 (After Trimming) non-synonymous Chr12: 112194954
SRR408630 CFAP69 Stopgain Chr7: 90245542
was found between PLK3 and AML however; he et al. did find a relation between
Plk1 and AML [109].
In another study conducted by Brandwein and by Renner et al., they also found
that Plk1 was overexpressed in multiple tumor tissues which included AML. While
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PLK1 was overexpressed, PLK3 was found to be down-regulated in many cancerous
tissues [110] [111]. Berg et al., found that other PLK genes such as PLK2 and PLK3
can act as tumor suppressor genes in vivo [112]. Strebhardt et al. concluded that
PLK1 overexpression could result in oncogenic transformation, and ectopic expres-
sion of PLK3 induces apoptosis. The activity of PLK3 is then rapidly increased with
DNA damage and cellular stress leaving the expression level unchanged. It was also
suggested that the PLK3 was involved in DNA damage and apoptosis through p53
pathway. On inducing mice with PLK3, they found tumors in many organs, many
of which were large suggesting angiogenesis. There were no relations made between
AML and PLK3 though [113]. GTF3C5 was studied by Qian et. al, where the study
aimed to observe the cytogenetic and genetic pathways involved in AML. One of the
experiments involved identification of cooperating cancer genes and obtaining their
retroviral integration sites. Common insertion sites were obtained from a database
called Retroviral Tagged Cancer Gene Database [114]. From the database they ob-
tained two CISs one of which was found to be 23kb upstream of GTF3C5 locus.
With this they concluded that the gene plays an important role in AML. EGR2 was
also found to play an important role in AML as it promotes monocytic differentia-
tion [115].
Other genes which were studied for AML was GPR182 by Kechele et al., where
they studied the suppressor qualities of GPR182 gene to stop adenoma formation.
It was seen that GPR182 was among the genes which was severely altered in model
zebrafish with AML [90]. The rest of the novel variants found, i.e., QSOX2, MY-
CBPAPA, DIRAS1, POU4F2, ATP13A2, TEX2, SURF6, HECTD4, and CFAP69
were not much studied with regards to their involvement in the formation of AML.
CFAP69 has no data available concerning its mutational frequency or its ability as
an oncogene.
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Fig. 4.3. In this figure, variant obtained from the SRR408623 sample
is shown. Here, the novel variant is located in Chromosome X:150470758
positions where nucleotide base changes from C to G. Here, the MAMLD1
gene is found to be responsible for this mutation.
4.5 Gene Ontology (GO) & Protein-protein interaction (PPI) Analysis
The functional enrichment of variant genes are examined through DAVID func-
tional annotation tool. Table B.8 shows the statistically-enriched GO terms under
“cellular component”, “molecular function”, and “biological process” with their cor-
responding p-value. Most significant terms are related to nucleoplasm part under cel-
lular component with three gene count having p-value 9.3E-02. In addition, among 22
variant genes, five genes are involved in transcription regulator activity with p-value
7.1E-2. On the other hand, protein-protein interaction network work using variant
genes are shown in Fig. C.2. The network consists of a total of three nodes and four
edges. In this network two variants genes PLK3 (Threonine-Protein Kinase) and SF1
(Splicing Factor 1) are connected via CDC5L (Cell Division Cycle 5 Like).
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4.6 Chapter Summary
Apart from AML, most of the variants obtained from this study have an associa-
tion in other diseases as well (see Table B.7). To sum up, most of the variants obtained
were non-synonymous SNVs, apart from them EGR2, GTF3C5, and SURF6 are non-
frameshift and PLK3, CFAP69, and SF1 are stop-gain mutation. These identified
genes may be helpful in enhancing the underlying molecular mechanism of AML.
The research could be further elaborated in finding out the role of such novel genes
for metabolic pathways and develop molecular targeted therapies for AML. In the
previous chapter, normalised RNA-seq data was used to classify diseases and to iden-
tify biomarkers, however, in this chapter raw methylated DNA data is used which
requires different pre-processing steps and algorithms such as Deepvariant in order to
find novel variants and their chromosomal location.
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Chapter 5
Conclusions and Future Work
5.1 Conclusions
In this thesis, the AAE based feature extraction method is developed, and its
usefulness is analysed. Also, a pipeline has been developed for mutation detection,
and novel mutations have been identified.
As genetic data contains lots of features with limited sample, it creates significant
amount of noise in the data. AAE based feature reduction technique extracts mean-
ingful features that enable classification of cancer cells. First, to verify the usefulness
of AAE, various classifiers were used and compared its performance with existing
state-of-the-art methods. AAE extracted features performed excellent and consistent
across various classifiers. Classification of cancer types at an early stage increases
the chances for successful treatment. AAE based feature extraction method auto-
matically find correlation in the data and extract new features which helps classifiers
to classify cancer subtypes. This computational technique can help pathologist to
diagnose diseases more accurately.
Besides, it was possible to obtain biological information by studying the weight
matrix of AAE. Encoded genes were ranked according to their weights and top 50
genes are selected. Those genes were taken for gene ontology and pathway analy-
sis and their molecular function proved to be asssociated with breast cancer. From
findings, it can be concluded that this AAE based feature extraction technique has
much potential in cancer sub-type classification and biomarker identification. Find-
ing novel biomarkers from RNA-seq data are valuable in predicting prognosis, and
personalized medicine. Moreover, biomarkers can be helpful in detecting therapeutic
and monitoring treatment.
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To find genetic variation in DNA methylated data, bioinformatics pipeline is de-
veloped where three different variant callers such as Freebayes, GATK and neural
network based Deep-Variant are used. This pipeline applied to DNA methylated
leukemia samples and 22 novel variants were obtained. Furthermore, various down-
stream analysis such as GO and PPI has been performed to know the biological
function and interaction between the mutated genes. Also, chromosomal location
of the mutated genes have been identified. Identifying location of genetic variation
is important in terms of predicting functional signicance or functional annotation.
Overall, genetic variation can assist to determine targered therapies and personalized
medicine.
One limitation of deep learning based method is that it requires lots of data
however as genetic data-sets keep increasing, AAE based method has lots of potential
in cancer research. Also, variants obtained from leukemia samples could provide
direction for further biological evaluation.
5.2 Recommendation for future Work
The following recommendations are made for future research studies:
1) It is recommended to implement AAE model on different bigger data-sets with
more hidden layers and optimise the hyper-parameters accordingly.
2) Instead of using grid search technique, AAE architecture in conjunction with
a genetic algorithm can be implemented to optimise its hyper-parameters more effi-
ciently.
3) Better hardware with higher GPU cluster is recommended for training deeper
AAE.
4) Cross cancer biomarker can be identified if AAE can be applied to heterogeneous
cancer data.
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5) Mutation detection pipeline can be applied to different genomic data to identify
the mutation. Also, based on the need of the researchers, a different biological plan
can be implemented on this pipelines using this methylated DNA dataset.
It is expected that this thesis provides a strong basis for ongoing research in deep
learning and bioinformatics. In this thesis, a new architecture for feature extraction
and pipeline for mutation detection are developed. Then the proposed method is
compared with traditional methods, and its effectiveness is established by comparing
their results.
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Chapter A
Algorithms
Algorithm 1 Algorithm named TopGene for obtaining highly weighted genes
Input : Weight Matrix (Gene × Weight)
Output : gene list ← Top 50 highly weighted genes
1: procedure To obtain highly weighted gene
2: for gene ← 0 to totalGene do
3: weight sum← 0
4: gene weight list; . empty list
5: for node ← 0 to totalNode do
6: weight sum← weight sum+ weight(node)
7: end for
8: Append gene weight list← (gene× weight sum)
9: end for
10: Sort gene weight list by weight
11: Select top 50 highly weighted genes from gene list ← gene weight list
12: Return gene list
13: end procedure
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Algorithm 2 Pseudocode of our methodological approach for classification
procedure Procedure for cancer classification
dataset⇐ {“BRCA”}
over sampler⇐ {“SMOTE” }
normalizer⇐ {“Quantile transformer” }
feature extractor⇐ {“AAE”, “VAE”, “DAE”, “AE” }
classifier⇐ {“MLP”, “SVM”, “RF”, “LR” etc. }
performance metrics⇐ {“Accuracy”, “Precision”, “Recall” etc.}
X, Y⇐ load data(dataset) . Here, X is data sample and Y is label
for k=1→ 5 do . for five fold cross validation
X train, Y train, X test, Y test ⇐ split data(X,Y,k)
fitted⇐ over sampler(X train,Y train)
X train⇐ predict sampler(X train, fitted) . only training data is
over-sampled
fitted⇐ normalizer(X train norm)
X train norm⇐ predict normalizer(X train sampled, fitted)
X test norm⇐ predict normalizer(X test, fitted)
model trained⇐ feature extractor(X train norm) . feature extraction is
unsupervised
fine tuned⇐ fine tuning(X train norm, Y train, model trained) . fine tun-
ing is supervised State X train feature⇐ predict feature(X train norm, fine tuned)
X test feature⇐ predict feature(X test norm, fine tuned)
fitted⇐ classifier(X train feature, Y train)
Y test prediction⇐ predict classifier(X test feature, fitted
score[k]⇐ performance metrics(Y test,Y test prediction}
end for
results⇐ mean(score)
end procedure
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Chapter B
Tables
Table B.1.
Specification of computer used in the experiment
OS Ubuntu 14.04.4 LTS
CPU 2× Intel Xeon CPU E52630V3 2.4GHz
GPU 6× NVIDIA Tesla K80 (12GB each)
Memory 128 GB
72
Table B.2.
Comparison of various feature extraction techniques using BRCA dataset
with twelve different classifiers. Five-fold cross validation were performed
during evaluation.
Feature Classifier Accuracy F1-Score Recall Precision AUC MCC Kappa
AAE
DecisionTree 0.839388483 0.836249942 0.839388483 0.844108326 0.847653599 0.750988818 0.749160982
GaussianNaiveBayes 0.849622936 0.847029478 0.849622936 0.85426443 0.954855911 0.769002453 0.766501187
GradientBoosting 0.839621327 0.839088704 0.839621327 0.849173344 0.935249701 0.756213173 0.754086964
K-nearestNeighbors 0.854514302 0.853827909 0.854514302 0.857487812 0.901797375 0.77617233 0.774851882
LinearDiscriminantAnalysis 0.846303812 0.847388265 0.846303812 0.856157931 0.942246196 0.768003317 0.765195144
LogisticRegression 0.851193839 0.85247222 0.851193839 0.857671964 0.967289315 0.77328451 0.772255133
MultiLayerPerceptron 0.849499173 0.850309202 0.849499173 0.854115081 0.9646908 0.770009528 0.769177168
QuadraticDiscriminantAnalysis 0.833009526 0.819977387 0.833009526 0.842746164 0.920429012 0.740315082 0.734175864
RandomForest 0.849443833 0.848652248 0.849443833 0.851384158 0.963209116 0.768292222 0.767233376
SupportVectorMachine 0.854473431 0.855198005 0.854473431 0.85960089 0.966842232 0.776959628 0.775883708
VotingClassifier 0.851180522 0.852628473 0.851180522 0.859301306 0.964492001 0.772955155 0.771627221
XGBoost 0.847858688 0.846767381 0.847858688 0.854791386 0.940914777 0.768282568 0.765991729
PCA
DecisionTree 0.753736615 0.751592834 0.753736615 0.75418319 0.791098601 0.622354019 0.620818118
GaussianNaiveBayes 0.710472338 0.657722762 0.710472338 0.705645881 0.919806712 0.548915033 0.489031294
GradientBoosting 0.839539354 0.834799917 0.839539354 0.842904871 0.947004649 0.751577474 0.7488104
K-nearestNeighbors 0.800137319 0.771107037 0.800137319 0.798929207 0.841333945 0.68760381 0.669386738
LinearDiscriminantAnalysis 0.841274672 0.840933216 0.841274672 0.847812351 0.952886432 0.757780367 0.755420527
LogisticRegression 0.856231565 0.851939132 0.856231565 0.853748179 0.972522922 0.780780828 0.778275478
MultiLayerPerceptron 0.864484286 0.860142917 0.864484286 0.867868279 0.971902183 0.792014794 0.788583467
QuadraticDiscriminantAnalysis 0.763384783 0.714156607 0.763384783 0.722590756 0.822266525 0.633382512 0.594658536
RandomForest 0.821544982 0.814433738 0.821544982 0.823637601 0.95407046 0.723236263 0.720677223
SupportVectorMachine 0.502520441 0.336148077 0.502520441 0.252544581 0.911284185 0 0
VotingClassifier 0.864457867 0.862053862 0.864457867 0.867286196 0.968348976 0.792500149 0.790122967
XGBoost 0.790163958 0.794978228 0.790163958 0.818087056 0.927292824 0.693161313 0.685385267
VAE
DecisionTree 0.774698501 0.773041542 0.774698501 0.77944041 0.794796607 0.652719602 0.649762969
GaussianNaiveBayes 0.849511829 0.84608678 0.849511829 0.857923589 0.966968445 0.768035279 0.765997897
GradientBoosting 0.826188391 0.817940653 0.826188391 0.827152685 0.954982207 0.730262282 0.723697307
K-nearestNeighbors 0.836298391 0.824661131 0.836298391 0.845570676 0.873404354 0.747587069 0.736835105
LinearDiscriminantAnalysis 0.846299758 0.842439558 0.846299758 0.847203539 0.95363347 0.762176099 0.760102351
LogisticRegression 0.849485398 0.844308487 0.849485398 0.856267011 0.965020919 0.768293372 0.765512002
MultiLayerPerceptron 0.844443382 0.838125267 0.844443382 0.849904151 0.96736337 0.760232579 0.757019396
QuadraticDiscriminantAnalysis 0.816545417 0.780158188 0.816545417 0.756123651 0.942402546 0.712892589 0.701145717
RandomForest 0.842802908 0.834898783 0.842802908 0.837045414 0.959560767 0.756357916 0.752568376
SupportVectorMachine 0.741605395 0.696701387 0.741605395 0.748949679 0.932980503 0.598378311 0.547314634
VotingClassifier 0.849485398 0.844008731 0.849485398 0.856164611 0.96482982 0.768117807 0.765113451
XGBoost 0.809727449 0.804951436 0.809727449 0.813582187 0.93342438 0.707593404 0.703730845
DAE
DecisionTree 0.756745202 0.76136685 0.756745202 0.772239554 0.80156567 0.635143351 0.63293761
GaussianNaiveBayes 0.803209125 0.804638936 0.803209125 0.823718224 0.944553731 0.712128676 0.70478357
GradientBoosting 0.827940633 0.824491699 0.827940633 0.82558335 0.952923342 0.735924476 0.734120872
K-nearestNeighbors 0.810029836 0.801003462 0.810029836 0.804152958 0.870360912 0.704581917 0.701436887
LinearDiscriminantAnalysis 0.829633057 0.827492948 0.829633057 0.831083486 0.946805835 0.737863582 0.73599749
LogisticRegression 0.851316231 0.844226923 0.851316231 0.843058001 0.968190793 0.771852926 0.769832134
MultiLayerPerceptron 0.85132957 0.845358555 0.85132957 0.846808679 0.965392221 0.771412082 0.76978905
QuadraticDiscriminantAnalysis 0.659424406 0.660667302 0.659424406 0.741780811 0.87448019 0.52613188 0.499096967
RandomForest 0.833091515 0.83153543 0.833091515 0.834235186 0.955596555 0.743636066 0.74263735
SupportVectorMachine 0.504159785 0.339680007 0.504159785 0.298859443 0.888868625 0.02021046 0.004147157
VotingClassifier 0.849608925 0.844833196 0.849608925 0.846621453 0.96489829 0.768181112 0.766579872
XGBoost 0.798196022 0.798449186 0.798196022 0.805404252 0.935335233 0.694800308 0.692319846
AE
DecisionTree 0.776870101 0.777640872 0.776870101 0.788093191 0.813045073 0.664381503 0.661059745
GaussianNaiveBayes 0.824594203 0.824433767 0.824594203 0.836907819 0.953435819 0.735705809 0.731511428
GradientBoosting 0.837817784 0.834262996 0.837817784 0.846374018 0.953101885 0.752539948 0.748924611
K-nearestNeighbors 0.806641389 0.795330514 0.806641389 0.797187143 0.860574433 0.700721583 0.696349558
LinearDiscriminantAnalysis 0.832762907 0.830316602 0.832762907 0.833601319 0.949007155 0.741437876 0.739739786
LogisticRegression 0.839649344 0.834615387 0.839649344 0.837407037 0.96738091 0.754727258 0.752788666
MultiLayerPerceptron 0.839717317 0.833825499 0.839717317 0.831991725 0.966478992 0.75464963 0.752927149
QuadraticDiscriminantAnalysis 0.769696892 0.752339499 0.769696892 0.785987804 0.917625177 0.656824961 0.640123808
RandomForest 0.856207382 0.855261686 0.856207382 0.862356696 0.961018755 0.781087521 0.778914687
SupportVectorMachine 0.502520441 0.336148077 0.502520441 0.252544581 0.898905424 0 0
VotingClassifier 0.846178704 0.84271771 0.846178704 0.845300405 0.963799657 0.764311356 0.762747477
XGBoost 0.826135756 0.825636444 0.826135756 0.833472159 0.941867158 0.736588773 0.733891252
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Table B.3.
Benchmarking of various feature extractor while classifying various cancer
subtypes using BRCA dataset.
Feature Extractor CPU Usage (%) Memory (MB) Running Time
AAE (2 layer) 24.1 2164 10 min 54 sec
AE (2 layer) 21.8 2335 20 min 38 sec
PCA (2 layer) 18.7 1402 2 min 28 sec
VAE (2 layer) 20.2 2254 19 min 30 sec
DenoisingAE (2 layer) 22.2 2546 20 min 43 sec
Table B.4.
Benchmarking of various feature extractor while extracting biologically rel-
evant genes using BRCA dataset.
Feature Extractor CPU Usage (%) Memory (MB) Running Time
AAE (Single layer) 23.5 1946 1 min 13 sec
AAE (2 layer) 21.6 2087 1 min 57 sec
AAE(3 layer) 29.5 2121 2 min 1 sec
VAE (Single layer) 24.1 1837 1 min 4 sec
AE (Single layer) 24.7 1840 1 min 12 sec
DenoisingAE (Single layer) 25.7 2036 1 min 14 sec
PCA 26.2 1012 25 sec
NMF 39.9 916 47 sec
FastICA 30.3 1342 27 sec
FactorAnalysis 27.5 1138 26 sec
LDA 61.2 884 16 min 20 sec
tSVD 26.7 913 24 sec
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Table B.5.
Results of pathway analysis using various feature extraction methods on
BRCA data-set.
Algorithm Top Pathway P-value
AAE (Single layer) Olfactory transduction 5.23e-2
AAE (2 layer) No Significant pathway
AAE (3 layer) Neuroactive ligand-receptor interaction 1.97e-2
AE No significant pathway
DAE No significant pathway
PCA No Significant Pathway
VAE No Significant Pathway
NMF No Significant Pathway
ICA No Significant Pathway
Table B.6.
Results of gene enrichment analysis using various feature extraction meth-
ods further validated on UCEC data-set.
Algorithm Molecular Function P-value
AAE (Single layer)
Metal ion binding 5.44e-2
Transition metal ion binding 6.38e-2
AAE (2 layer) Small conjugating protein ligase activity 5.59e-2
AAE (3 layer) Drug binding 1.02e-2
AE Hydrogen ion transmembrane transporter activity 1.82e-2
PCA Calcium ion binding 3.42e-3
VAE Olfactory receptor activity 4.25e-6
NMF snRNA binding 2.43e-2
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Table B.7.
The novel variants with associated cancer and their primary expression
Gene Name Expression Associated Cancer(Mutation Frequency)
MAMLD1 Broad Expression, most in Testis (RPKM 8.2) Stomach Adenocarcinoma (3.73%)
SLC22A6 Restricted to Kidney (RPKM 150.9) Cutaneous Melanoma (3.79%)
DMWD Ubiquitous Expression in Testis (RPKM 11.5) Oesophageal Carcinoma (2.05%)
CDK11A Ubiquitous Expression in Bone Marrow (RPKM 22.4) Cutaneous Melanoma (1.08%)
SLC2A5 Biased Expression in Duodenum (RPKM 33.7) Cutaneous Melanoma (2.17%)
QSOX2 Ubiquitous Expression in Lymph Nodes (RPKM 8.6) Non-Small Cell Lung Carcinoma (3.23%)
EGR2 Biased Expression in Thyroid (RPKM 66.1) Lung Squamous Cell Carcinoma (1.72%)
SF1 Ubiquitous Expression in Bone Marrow (RPKM 62.1) Cutaneous Melanoma (2.17%)
ZFHX3 Ubiquitous Expression in Thyroid (RPKM 3.0) Uterine Corpus Endometrioid Carcinoma (12.16%)
MYCBPAP Restricted Expression toward Testis (RPKM 33.9) Cutaneous Melanoma (3.79%)
DIRAS1 Biased Expression in Brain (RPKM 26.6) Lung Squamous Cell Carcinoma (1.15%)
DOK2 Broad Expression, most in Spleen (RPKM 18.2) Oesophageal Carcinoma (1.37%)
PLK3 Ubiquitous Expression in Bone Marrow (RPKM 16.1) Bladder Carcinoma (2.04%)
GPR182 Biased Expression in Spleen (RPKM 5.1) Small Cell Lung Carcinoma (1.45%)
POU4F2 Low Expression Observed in Reference Dataset Stomach Adenocarcinoma (2.48%)
ATP13A2 Ubiquitous Expression in Brain (RPKM 19.6) Bladder Carcinoma (4.08%)
TEX2 Broad Expression in Testis (RPKM 15.4) Lung Squamous Cell Carcinoma (2.87%)
PKHD1 Biased Expression in Kidney (RPKM 4.0) Small Cell Lung Carcinoma (23.19%)
GTF3C5 Ubiquitous Expression in ovary (RPKM 17.0) Stomach Adenocarcinoma (1.86%)
SURF6 Ubiquitous Expression in Colon (RPKM 12.0) Oesophageal Carcinoma (2.05%)
HECTD4 Ubiquitous Expression in Brain (RPKM 8.7) Bladder Carcinoma (9.18%)
CFAP69 Broad Expression in Prostate (RPKM 3.6) No Data Available
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Table B.8.
Results of GeneOntology (GO) enrichment analysis using variants genes
are shown.
Category Term Gene Count P-Value
Cellular component Nucleoplasm Part 3 9.3E-2
Molecular Function Transcription Regulator Activity 5 7.1E-2
Biological Process Cell Cycle 5 2.1E-2
Biological Process Axonogenesis 3 3.0E-2
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Chapter C
Figures
Fig. C.1. The olfactory transduction pathway obtained from AAE model.
The GC-D expressing ORNs and Odorant (highlighted in red) are oncogenic
activators responsible for triggering olfactory transduction pathway
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Fig. C.2. In this figure, Interaction between proteins are shown. Here,
PLK3 variant gene are connected to SF1 variant gene via CDC5L
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Codes
D.1 AAE Architechture
1 de f mode l generator ( latent d im , input shape , hidden dim=1000) :
2 re turn Sequent i a l ( [
3 Dense ( hidden dim , name=” generator h1 ” ,
4 input dim=latent d im , a c t i v a t i o n=’ tanh ’ ) ,
5 Dense ( input shape [ 0 ] , name=” generator output ” ,
6 a c t i v a t i o n=’ s igmoid ’ ) ] ,
7 name=” generato r ” )
8
9 de f model encoder ( latent d im , input shape , hidden dim=1000) :
10 x = Input ( input shape , name=”x” )
11 h = Dense ( hidden dim , name=” encoder h1 ” , a c t i v a t i o n=’ tanh ’ ) ( x )
12 z = Dense ( latent d im , name=”encoder mu” , a c t i v a t i o n=’ tanh ’ ) (h)
13 re turn Model (x , z , name=” encoder ” )
14
15 de f mode l d i s c r im inato r ( input shape , output dim=1, hidden dim=1000) :
16 z = Input ( input shape )
17 h = z
18 h = Dense ( hidden dim , name=” d i s c r im ina to r h1 ” ,
19 a c t i v a t i o n=’ tanh ’ ) (h)
20 y = Dense ( output dim , name=” d i s c r im ina t o r y ” ,
21 a c t i v a t i o n=” sigmoid ” ) (h)
22 re turn Model ( z , y )
23
24 de f aae model ( path , adv e r s a r i a l op t im i z e r , xtra in , ytra in , xtes t , ytes t ,
encoded dim=100 , img dim=25, nb epoch=2) :
25 l a t ent d im = encoded dim
26 input shape = ( img dim , )
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27 generato r = mode l generator ( latent d im , input shape )
28 encoder = model encoder ( latent d im , input shape )
29 autoencoder = Model ( encoder . inputs ,
30 generato r ( encoder ( encoder . inputs ) ) , name=”autoencoder ” )
31 d i s c r im ina t o r = mode l d i s c r im inato r ( input shape )
32 # assemble AAE
33 x = encoder . inputs [ 0 ]
34 z = encoder (x )
35 xpred = generato r ( z )
36 y r e a l = d i s c r im ina t o r ( x )
37 yfake = d i s c r im ina t o r ( xpred )
38 aae = Model (x , f ix names ( [ xpred , yfake , y r e a l ] ,
39 [ ” xpred” , ” yfake ” , ” y r e a l ” ] ) )
40 # pr in t summary o f models
41 encoder . summary ( )
42 generato r . summary ( )
43 d i s c r im ina t o r . summary ( )
44 # bui ld adv e r s a r i a l model
45 generat ive params = genera tor . t r a i n ab l e we i gh t s + encoder .
t r a i n ab l e we i gh t s
46 model = Adversar ia lModel ( base model=aae ,
47 player params=[ generat ive params ,
48 d i s c r im ina t o r . t r a i n ab l e we i gh t s ] ,
49 player names=[” generator ” , ” d i s c r im ina t o r ” ]
50 )
51 model . a dv e r s a r i a l c omp i l e ( a dv e r s a r i a l o p t im i z e r=
52 adv e r s a r i a l o p t im i z e r
53 p l ay e r op t im i z e r s =[Adadelta ( ) , Adadelta ( ) ] ,
54 l o s s={” yfake ” : ” b ina ry c ro s s en t ropy ” ,
55 ” y r e a l ” : ” b ina ry c ro s s en t ropy ” ,
56 ”xpred” : ” b ina ry c ro s s en t ropy ” } ,
57 p layer compi l e kwargs =[{” l o s s w e i g h t s ” :
58 {” yfake ” : 1e−4, ” y r e a l ” : 1e−4, ”xpred” : 1
e1 }} ]∗2)
59 n = xt ra in . shape [ 0 ]
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60 y = [ xtra in , np . ones ( ( n , 1) ) , np . z e r o s ( ( n , 1) ) ,
61 xtra in , np . z e r o s ( ( n , 1) ) , np . ones ( ( n , 1) ) ]
62 nt e s t = xt e s t . shape [ 0 ]
63 y t e s t = [ xtes t , np . ones ( ( ntest , 1) ) ,
64 np . z e ro s ( ( ntest , 1) ) , xtes t ,
65 np . z e ro s ( ( ntest , 1) ) , np . ones ( ( ntest , 1) ) ]
66 h i s t o r y = model . f i t ( x=xtra in , y=y ,
67 va l i d a t i on da t a=(xtes t , y t e s t ) ,
68 epochs=nb epoch , b a t ch s i z e =128 ,
69 s h u f f l e=Fal se )
70 df = pd . DataFrame ( h i s t o r y . h i s t o r y )
71 df . t o c sv ( os . path . j o i n ( path , ” a a e n ew ac t i v a t i on h i s t o r y . csv ” ) )
72 encoder . save ( os . path . j o i n ( path , ” aae encoder . h5” ) )
73 generato r . save ( os . path . j o i n ( path , ” aae decoder . h5” ) )
74 K. c l e a r s e s s i o n ( )
D.2 Fine Tuning
1 y t r a i n b i n a r i z e = l a b e l b i n a r i z e ( y t ra in , c l a s s e s = [0 , 1 , 2 , 3 ] )
2 y t e s t b i n a r i z e = l a b e l b i n a r i z e ( y t e s t , c l a s s e s = [0 , 1 , 2 , 3 ] )
3
4 model=load model ( ’ . / saved models /AAE/OneHidden/ aae encoder . h5 ’ )
5 #load the AAE tra ined model
6 model . summary ( )
7
8 t r a n s f e r l a y e r=model . g e t l a y e r ( ’ encoder mu ’ )
9 #pu l l the l a s t l a y e r
10 aae prev model=Model ( inputs=model . input , outputs=t r a n s f e r l a y e r . output )
11 new model=Sequent i a l ( )
12 new model . add ( aae prev model )
13 new model . add (Dropout (p = 0 .001 ) )
14 # add dropout
15 new model . add (Dense ( un i t s = 4 , a c t i v a t i o n = ’ softmax ’ , name=’
new layer added ’ ) )
16 #add output l ay e r with four neuron s i n c e we have four c l a s s
17 de f p r i n t l a y e r t r a i n a b l e ( ) :
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18 f o r l a y e r in aae prev model . l a y e r s :
19 pr in t ( ” {0} :\ t {1}” . format ( l ay e r . t r a inab l e , l a y e r . name) )
20
21 f o r l a y e r in aae prev model . l a y e r s :
22 l a y e r . t r a i n ab l e=False
23
24 p r i n t l a y e r t r a i n a b l e ( )
25 aae prev model . t r a i n ab l e=True
26
27 #Now I t i s time to Modify the Layer
28
29 f o r l a y e r in aae prev model . l a y e r s :
30 t r a i n ab l e=( ’ encoder mu ’ in l ay e r . name)
31 #modify the l a s t l a y e r only
32 #t r a i n ab l e =( ’ encoder h2 ’ in l ay e r . name or ’ encoder mu ’ in l ay e r . name
)
33 l a y e r . t r a i n ab l e=t r a i n ab l e
34 p r i n t l a y e r t r a i n a b l e ( )
35
36 new model . compi le ( opt imize r = ’ adade l ta ’ ,
37 l o s s = ’ c a t e g o r i c a l c r o s s e n t r o py ’ ,
38 metr i c s = [ ’ accuracy ’ ] )
39
40 h i s t o r y=new model . f i t ( x t ra in , y t r a i n b i n a r i z e ,
41 ba t ch s i z e = 20 , epochs = 50 ,
42 va l i d a t i on da t a=
43 ( x t e s t , y t e s t b i n a r i z e )
44 )
45
46 s co r e = new model . eva luate ( x t e s t , y t e s t b i n a r i z e , verbose=1,
b a t ch s i z e =20)
47
48 pr in t ( ”Test Accuracy : \n%s : %.2 f%%” % ( new model . metr ics names [ 1 ] , s c o r e
[ 1 ] ∗ 1 00 ) )
49
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50 path=’ . / saved models /AAE/OneHidden/ ’
51 df = pd . DataFrame ( h i s t o r y . h i s t o r y )
52 df . t o c sv ( os . path . j o i n ( path , ’ f i n e t u n e d h i s t o r y . csv ’ ) )
53 new model . summary ( )
54 new model . l a y e r s . pop ( )
55 new model . summary ( )
56 new model . l a y e r s . pop ( )
57 #de l e t e the l a s t two l a y e r s
58 new model . summary ( )
59 new model . save ( os . path . j o i n ( path , ’ en code r f i n e tuned . h5 ’ ) )
60
61 model = load model ( ’ . / saved models /AAE/OneHidden/ encode r f i n e tuned . h5 ’ )
62 model . summary ( )
63 x t r a i n = model . p r ed i c t ( x t r a i n )
64 pr in t ( ’ X Train Shape a f t e r AAE : ’ , x t r a i n . shape )
65 x t e s t = model . p r ed i c t ( x t e s t )
66 pr in t ( ’ X Test Shape a f t e r AAE : ’ , x t e s t . shape )
D.3 Extract Weight form Latent Space
1 weight = load model ( ’ . / saved models /MOLECULAR/Weight Analys is /AAE/
aae encoder . h5 ’ )
2 encoded aae=weight . p r ed i c t (X)
3 weights = [ ]
4
5 f o r l a y e r in weight . l a y e r s :
6 weights . append ( l ay e r . g e t we i gh t s ( ) )
7 d = pd . DataFrame ( weights )
8 pr in t ’Weight l ay e r shape : ’ , d . shape
9
10 #fo r one hidden l ay e r
11 i n t e rmed i a t e we i gh t d f = pd . DataFrame ( weights [ 1 ] [ 0 ] )
12 i n t e rmed i a t e we i gh t d f 2 = pd . DataFrame ( weights [ 2 ] [ 0 ] )
13 ab s t r a c t ed we i gh t d f = in t e rmed i a t e we i gh t d f . dot (
i n t e rmed i a t e we i gh t d f 2 )
14 #we need to apply dot product o f two weight metr i c s
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15 weight matr ix=in t e rmed i a t e we i gh t d f
D.4 Analyze and sort Weight Matrix
1 de f we i gh t ana l y s i s ( weight matr ix , w e i g h t f i l e ,
2 encoded matrix , e n c od ed f i l e ,
3 g e n e f i l e , index , f e a t u r e d i s t r i b u t i o n ) :
4
5 e n f i l e =os . path . j o i n ( e n c od e d f i l e )
6 encoded = pd . DataFrame ( encoded matr ix )
7 encoded . t o c sv ( e n f i l e , sep=’ \ t ’ )
8
9 w t f i l e = os . path . j o i n ( w e i g h t f i l e )
10 wt matrix = weight matr ix . s e t i nd ex ( index ) # i t i s a l r eady in
dataframe
11 wt matrix . t o c sv ( w t f i l e , sep=’ \ t ’ )
12 gene so r t ed = wt matrix . sum( ax i s=1) . s o r t v a l u e s ( ascending=False )
13
14 g n f i l e = os . path . j o i n ( g e n e f i l e )
15 gene matr ix = pd . DataFrame ( gene so r t ed )
16 gene matr ix . t o c sv ( g n f i l e , sep=’ \ t ’ )
17
18 g = sns . FacetGrid ( gene matrix , sharex=False , sharey=False )
19 g .map( sns . d i s t p l o t , 0 )
20 g . s a v e f i g ( f e a t u r e d i s t r i b u t i o n , dpi=300)
21
22 pr in t ( ’ After Applying Dimension Reduction ’ , encoded . shape )
23 pr in t ( ’Weight Matrix Shape ’ , wt matrix . shape )
24 #pr in t ( ’Sum of Encoded Node and Sorted ’ , sum node act iv i ty )
